Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Active Lupus Nephritis
NCT04868838Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2021
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in lupus nephritis (LN), sponsored by Mayo Clinic. Primary endpoint: Complete or Partial Renal Remission Rate at 12 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT04868838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868838.